Terlivaz Injection, Powder, Lyophilized, For Solution
Product Images NDC 43825-200

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Terlivaz (NDC 43825-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mallinckrodt Hospital Products Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Terlivaz 01)

Figure 1 (Terlivaz 01)
The text provides instructions for administering TERLIVAZ with an initial dose of 0.85 me (1 vial) every 6 hours. A baseline serum creatinine should be recorded on Day 1, and subsequent serum creatinine levels assessed on Day 4. If serum creatinine has decreased by 30% or more from baseline, continue TERLIVAZ at the same dose. If serum creatinine has decreased by less than 30% from baseline or is at or above baseline value, either increase the dose or discontinue treatment. TERLIVAZ should be continued until serum creatinine levels have been below 1.5 mg/dL for at least 24 hours or for a maximum of 14 days.*
FDA Label Image

Chemical Structure (Terlivaz 02)

FDA Label Image

Principal Display Panel (0.85 mg Vial Carton)

Principal Display Panel (0.85 mg Vial Carton)
This is a description for a drug provided in a single-use vial form. The drug is called Terlipressin, and it is used via intravenous delivery only. The medication contains 0.85mg of Terlipressin. One needs to discard unused portions. Before using, reconstitute Terlipressin with 5 mL of 0.9% Sodium Chloride Injection. It is best to store the reconstituted liquid in a refrigerator at a temperature between 2°C to 8°C. The medication needs to be used within 43 hours of preparation. The drug is manufactured in Italy by Pathenfala Spa and distributed by Mallinckrodt Pharmaceuticals in Bedminister, N 07921 USA. It comes with specific dosage instruction.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.